Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff

Astellas took a flier on women’s health when it bought out Ogeda and nonhormonal menopause candidate fezolinetant in early 2017 and then doubled down during a major restructuring just over a year later. Now, an early peek at late-stage studies bode well for Astellas’ chances — and it could be teeing up a fight with Bayer.